
	Where results make sense

Topic: Shire Pharmaceuticals Group

Related Topics

Alliance Unichem

United Utilities

Compass Group

Dixons Group

GUS plc

FTSE

3i

Associated British Foods

O2 plc

Allied Domecq

Public limited company

BHP Billiton

HSBC Holdings

Morrisons

Aviva

	Commission Legal Brief: Gryl v. Shire Pharmaceuticals Group / June 21, 2002
		The plaintiffs allege that defendants acquired options in Shire Pharmaceuticals Group PLC ("Shire") while the defendants were directors of Shire and then exercised some of their options and sold the resultingShire stock within six months of acquiring the options.
		The plaintiffs further contend that the Shire Board's approval was deficient in that it did not state that it was for the purpose of exempting the transactions from Section 16(b).
		Most notably, the plaintiffs point to a Shire board resolution from six weeks before the merger became effective, which states that "conditional upon completion of the Merger and admission of the Consideration Shares to the Official List, [the defendants] are hereby appointed as non-executive directors of the Company" (A785).
	www.sec.gov /litigation/briefs/shire062102.htm (5343 words)

	BRAND DEVELOPMENT - CONSUMER BRAND DEVELOPMENT - NAMING (Site not responding. Last check: 2007-11-03)
		Shire was also advised to distribute a letter to health care providers and to support independent continuing medical education on sudden cardiac death in pediatric patients for physicians in Canadian.
		At the time, Shire pointed out that these data were considered when the drug's label was updated in September 2004 to state that, in general, the drug should not be used in children or adults with structural cardiac abnormalities.
		Shire said the acquisition would "dilute earnings initially but be neutral in the second year and boost profits thereafter," according to a Reuters report.
	www.brandinstitute.com /ADDERALL_XR.asp (1626 words)

	Shire Pharmaceuticals Group plc
		Shire Pharmaceuticals Group plc Shire is an international specialty pharmaceutical company with a strategic focus on four therapeutic areas; central nervous system disorders, metabolic diseases, oncology and gastroenterology.
		Shire is actively searching to acquire further marketed products and development projects to enhance the potential for future growth, both organically and by acquisition.
		The results of Shire for the years ended December 31, 1995 and 1996 have not been audited as these were not statutory periods.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=105&STORY=/www/story/02-17-2000/0001144332 (475 words)

	Shire Receives Approval Letter for VYVANSE (lisdexamfetamine dimesylate) for the Treatment of ADHD
		Shire has a total of 3 ADHD (attention-deficit/ hyperactivity disorder) projects in full development, of which 2 are currently in Phase III or beyond.
		New River Pharmaceuticals does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
		Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
	www.shireadhdtreatments.com (2246 words)

	U.K.'s Shire buys BioChem Pharma for $4B - Dec. 11, 2000
		Shire (SHP), the U.K.'s fourth-largest pharmaceutical company by market capital, behind SmithKline Beecham PLC (SB-), AztraZeneca (AZN) and Glaxo Wellcome PLC (GLXO), saw its shares sink 209 pence, or more than 17 percent, to 1,020 pence in late Monday afternoon trading in London.
		Shire pledged to pay a fixed price of $37 worth of its stock for every BioChem share — provided that the average closing price of a Shire's American depositary receipt over the15 days prior to closing is between $47.20 and $70.80.
		Shire, whose footprint is primarily in North America and Europe, focuses on medicines for central nervous system disorders — including Adderall — and metabolic diseases, cancer and gastroenterological conditions.
	money.cnn.com /2000/12/11/europe/shire (558 words)

	treatment osteoperosis - Shire Pharmaceuticals
		Founded in 1986, Shire Pharmaceuticals Group plc is a rapidly growing international emerging pharmaceutical company with revenues for the full year 2002 of $1,037.3 million and an operating income of $327.038 million.
		Shire Laboratories Inc.(SLI) Shire Laboratories Inc.(SLI) is an advanced drug delivery company, which offers a full range of technologies and development capabilities.
		Shire dedicates multidisciplinary teams of highly experienced scientists to solve its partners' drug delivery problems covering all phases of projects from cell-based screening and pre-formulation to scale-up and commercialisation.
	www.shire-medications.co.uk /treatment_osteoperosis.html (421 words)

	Shire Pharmaceuticals buys New River - British Adderall maker Shire Pharmaceuticals Group PLC said ...
		Shire Pharmaceuticals buys New River - British Adderall maker Shire Pharmaceuticals Group PLC said...
		Shire said the purchase, approved by both companies' boards, will let it control the development and commercialization and capture the full economic value, of attention-deficit-disorder drug Vyvanse.
		Shire will finance the purchase through debt and the private placement of $800 million in shares to certain institutional shareholders, the company said.
	www.politicalgateway.com /news/read/64537 (146 words)

	Shire
		Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician.
		Shire focuses its business on attention deficit and hyperactivity disorder, human genetic therapies, gastrointestinal and renal diseases.
		Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
	www.shire.com /shire (109 words)

	Multislice CT Speeds Diagnosis of Chest Pain in Emergency Room (Site not responding. Last check: 2007-11-03)
		In the new study, patients with a clearly normal CT or nuclear scan were allowed to go home immediately, and those with a clearly abnormal scan were sent to the cardiac catheterization laboratory for further, invasive testing.
		In the CT group, patients with uncertain test results -- either because the images were not clear, or because there was only a moderate amount of disease in the coronary arteries -- also had a nuclear scan to help determine whether invasive testing would be needed.
		The Canadian research group created a more reliable set of standards by starting with the already validated adult cut-off points for 20-year-old women and men, then performing a statistical analysis to work backward to age 12.
	www.pslgroup.com /dg/2157B6.htm (1540 words)

	Shire Pharmaceuticals to Initiate Trial of AMPAKINE(R) CX516 in Patients with Attention Deficit Hyperactivity Disorder ...
		Should Shire elect to execute this agreement, Cortex would receive an upfront fee, milestone payments based on successful clinical and commercial development, research support for additional AMPAKINE compounds, and royalties on sales.
		The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells.
		The weakening or loss of these connections is thought to be responsible for memory difficulties from Alzheimer's disease and to contribute to cognitive dysfunction in schizophrenia.
	www.riskworld.com /pressrel/2001/01q2/PR01a056.htm (555 words)

	OSC - Orders & Rulings 2001 - In the Matter of Shire Pharmaceuticals Group PLC, Shire Acquisition Inc., 3829359 Canada ... (Site not responding. Last check: 2007-11-03)
		Shire is currently subject to the applicable informational requirements in the United Kingdom and of the United States Securities Exchange Act of 1934, as amended, and is not a reporting issuer or the equivalent under the Legislation.
		Except as otherwise required by applicable law or the Shire articles of association, the holder of the Special Voting Shares will be entitled to the number of votes, exercisable at any Shire meeting, equal to the number of Exchangeable Shares outstanding from time to time not owned by Shire and its affiliates, multiplied by three.
		Shire will send concurrently to all holders of Shire Ordinary Shares or Shire ADSs resident in Canada all disclosure material furnished to holders of shares of Shire Ordinary Shares or Shire ADSs resident in the United States including, without limitation, copies of its annual financial statements and all proxy solicitation materials.
	www.osc.gov.on.ca /Regulation/Orders/2001/ord_20010406_214_shire.jsp (6486 words)

	Shire and Noven Resubmitted NDA for MTS, a Candidate Treatment for Pediatric ADHD Patients - Health - RedOrbit (Site not responding. Last check: 2007-11-03)
		Shire and Noven Resubmitted NDA for MTS, a Candidate Treatment for Pediatric ADHD Patients
		Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal disease.
		Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
	www.redorbit.com /news/display?id=186627&source=r_health (644 words)

	PAPower: GOVERNOR RENDELL ANNOUNCES 400 NEW JOBS AT SHIRE PHARMACEUTICALS’ NEW U.S. HEADQUARTERS
		Shire Pharmaceuticals develops and markets specialty drugs for use in the treatment of central nervous system, gastrointestinal and renal diseases.
		Shire generates 70 percent of its more than $1 billion in annual revenue in the United States.
		Shire Pharmaceuticals expects to be in its new facility by September 2004.
	www.state.pa.us /papower/cwp/view.asp?Q=436985&A=11&papowerNav=\|31767\|&pp=12&n=1 (454 words)

	Shire Pharmaceuticals Group: 2003 Restated Results
		As indicated during the 2004 second quarter results presentation, the results for all quarterly periods previously presented during 2003 have been restated to reflect the expected disposal of our Biologics (vaccines) business, which was accounted for as a discontinued operation in the 2004 second quarter results announcement.
		Notes to editors Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc (Shire) is a global pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases.
		Management believes that the presentation of this non-US GAAP financial measure provides useful information to investors regarding Shire's underlying performance as the costs associated with the reorganization, the gain on the sale of an investment and the expected loss from discontinued operations are not part of the Company's ongoing operations.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=109&STORY=/www/story/08-03-2004/0002223737&EDATE= (776 words)

	Shire Pharmaceuticals Group PLC to buy BioChem Pharma Inc. for 20.98 times revenue \| Finance from AllBusiness.com
		The Deal: Shire Pharmaceuticals Group PLC has agreed to purchase BioChem Pharma Inc., of Montreal Canada, for $4 billion in stock.
		The acquisition reduces Shire's dependence on its Adderall drug for treating hyperactivity, which accounts for 35 percent of revenue.
		Discussion: BioChem Pharma Inc., through an alliance with United Kingdom pharmaceutical giant Glaxo Wellcome, has developed 3TC, the world's bestselling HIV treatment, which is used with Glaxo's Retrovir for the treatment of AIDS; and Zeffix, which is sold in over 30 countries for the treatment of chronic hepatitis B.
	www.allbusiness.com /finance/982752-1.html (484 words)

	Laparoscopic surgery does not reduce adhesions in gynaecological procedures
		Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international emerging pharmaceutical company with a strategic focus on four therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI), oncology, and anti-infectives.
		Shire also has three platform technologies: advanced drug delivery, lead optimisation for small molecules and Biologics.
		Shire's core strategy is based on research and development combined with in-licensing and a focus on key pharmaceutical markets.
	www.eurekalert.org /pub_releases/2003-07/aps-lsw070203.php (983 words)

	fluvira - Shire Pharmaceuticals (Site not responding. Last check: 2007-11-03)
		We want to achieve this by researching, developing and marketing products of the highest quality for the prevention and treatment of serious diseases, which are treated by medical specialists.
		We already have a wide range of products on the market but are using our search and development expertise to ensure that we can make more products available for these medically challenging diseases in the future.
		Shire Biologics Shire Biologics, part of the Shire Pharmaceuticals Group, has a global mandate to apply the most innovative science and technologies to discover, develop, produce and market novel human vaccines and biologics for infectious diseases.
	www.shire-pharmaceuticals.com /fluvira.html (354 words)

	Shire Pharmaceuticals Group plc - Company Profile - Food Business Review
		Sign-up for NewsAlerts on Shire Pharmaceuticals Group plc so that whenever news breaks on this company you are amongst the first to know.
		For the fiscal year ended December 2004, Shire generated revenues of $1,363.2 million, an increase of 12.5% from the restated figures of the previous year.
		To receive a complete and bespoke profile on Shire Pharmaceuticals Group plc, including SWOT analysis, order the full profile for just $125.
	www.food-business-review.com /companyprofile.asp?guid=39B0862A-AA0E-4B83-AE80-E70892133CE4 (137 words)

	ROLF STAHEL - SHIRE PHARMACEUTICALS GROUP PLC (SHPGY): TWST
		Over the last six years we've implemented six mergers, and Shire now has about 1,600 employees with a sales-per-employee ratio of approximately $500,000, nearly twice the ratio on average for S&P 500 companies.
		In regards to percent EPS growth for the year 2000, Shire was in the number-one position for the pharmaceutical industry globally.
		Shire has a very focused strategy and has operating companies in seven out of the eight key pharmaceutical markets in the world, and it has R&D operations in the UK, the US and in Canada.
	www.twst.com /notes/articles/nah240.html (296 words)

	Science & Medicine \| Shire Pharmaceuticals Licenses HIV Compound SPD754 to Australian Firm Avexa - Kaisernetwork.org
		U.K.-based Shire Pharmaceuticals Group on Monday announced that it has licensed its HIV compound SPD754 to Avexa, an Australian specialty anti-infectives company,
		SPD754, which is a non-nucleoside reverse transcriptase inhibitor, is currently in Phase II trials and is expected to reach the market in 2009.
		Shire officials said that this is one of the final steps in the group's divestment program, which is designed to focus efforts on later-stage investment in the areas of central nervous system, gastrointestinal and renal diseases,
	www.kaisernetwork.org /daily_reports/rep_index.cfm?DR_ID=27688 (279 words)

	PAPower: GOVERNOR RENDELL MARKS OPENING OF NEW SHIRE PHARMACEUTICALS HEADQUARTERS IN CHESTER COUNTY; GAT INVESTMENT ...
		WAYNE: Governor Edward G. Rendell marked the opening of Shire Pharmaceuticals’ new, U.S. corporate headquarters in Wayne just months after his economic development team crafted a package that would enable Shire to bring this important company to the commonwealth.
		Shire Pharmaceuticals Group, a global specialty-pharmaceuticals company based in Basingstoke, U.K., is in the process of creating 400 jobs within the next three years at the Chester County facility.
		Shire’s new U.S. headquarters is located at 725 Chesterbrook Boulevard in Wayne.
	www.state.pa.us /papower/cwp/view.asp?A=11&Q=443089&pp=12&n=1 (448 words)

	Developmental Methylphenidate Patch Scheduled for FDA Advisory Committee Review - Health - RedOrbit
		Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), renal diseases and human genetic therapies.
		Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products.
		Noven's prescription patches are sold in over 30 countries, and a range of new patches are being developed in collaboration with Shire Pharmaceuticals Group plc, Novartis Pharma AG, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others.
	www.redorbit.com /news/health/286125/developmental_methylphenidate_patch_scheduled_for_fda_advisory_committee_review/index.html?source=r_health (648 words)

	Shire Pharmaceuticals Group Information, Latest News, Articles
		Shire plc and its collaborative partner New River Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration has granted marketing approval for VYVANSE, for the treatment of Attention Deficit Hyperactivity Disorder.
		Shire will pay $64.00 in cash for each share of NRPH common stock, or approximately $2.6 billion for the fully diluted equity interest of New River.
		Shire plc announces today that it has agreed to acquire New River Pharmaceuticals Inc. for US$64 per New River share, or approximately US$2.6 billion in total, in an all cash transaction unanimously recommended by the Boards of both companies.
	www.market-day.net /news/shire-pharmaceuticals-group.php (392 words)

	AnorMED to get $3 million Shire payment - Boston.com
		AnorMED Inc. said Monday it will receive a $3 million milestone payment from Shire Pharmaceuticals Group PLC, based on Shire's recent licensing approval in Britain to sell Fosrenol as a treatment for high phosphate levels in the blood, which occurs in patients undergoing dialysis as a result of chronic kidney failure.
		NEW YORK --AnorMED Inc. said Monday it will receive a $3 million milestone payment from Shire Pharmaceuticals Group PLC, based on Shire's recent licensing approval in Britain to sell Fosrenol as a treatment for high phosphate levels in the blood, which occurs in patients undergoing dialysis as a result of chronic kidney failure.
		Under terms of the agreement, Shire agreed to pay AnorMED $18 million when Fosrenol was approved in the U.S. and $7 million when the drug was approved in European countries.
	www.boston.com /business/healthcare/articles/2006/09/25/anormed_to_get_3_million_shire_payment?mode=PF (219 words)

	Shire Brings Legal Suit Against Nostrum Pharmaceuticals : Epilepsy.com
		The complaint was filed in the U.S. District Court for the District of New Jersey.
		The lawsuit results from an ANDA (Abbreviated New Drug Application) filed by Nostrum for a generic version of the 300 mg dosage strength of CARBATROL(r), pursuant to which Nostrum provided notice that it would seek to market its generic product before the expiration of the '013 and '570 Patents.
		CARBATROL(r) is Shire's leading extended-release medication for the treatment of epilepsy.
	www.epilepsy.com /newsfeed/pr_1074177002.html (287 words)

Try your search on: Qwika (all wikis)